Compare Incyte Corporation (INCY) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Spotify Technology — how do they compare? Incyte Corporation trades at $121.47 (market cap $24.54B), while Spotify Technology trades at $489 (market cap $103.00B). The key difference: Spotify Technology is far larger — about 4.2× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.
| INCY | SPOT | |
|---|---|---|
Market Cap | $24.54B | $103.00B |
Sector | Health | Media |
52-Week High | $129.93 | $738.53 |
52-Week Low | $81.61 | $412.75 |
Enterprise Value | $20.04B | $92.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Spotify (SPOT) trades at $511.82, up 4.85% with a bullish technical outlook. The company reported strong Q2 2026 results with revenue growth and record gross margins, though earnings missed estimates due to higher AI and marketing costs. Analyst consensus is bullish with a $598.20 price target, supported by 61.5% buy ratings. Recent news highlights Spotify's initiative to label AI-generated artists, enhancing platform transparency.
The outlook remains positive with robust subscriber growth and monetization efforts, but risks include competitive pressures and cost management. Upside potential exists if execution continues, while misses on user growth or margin targets could weigh on the stock. The current valuation reflects optimism for sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
